Stock Traders Purchase High Volume of Put Options on Kodiak Sciences (NASDAQ:KOD)

Kodiak Sciences Inc. (NASDAQ:KOD) was the target of unusually large options trading activity on Thursday. Traders purchased 3,472 put options on the stock. This is an increase of 1,256% compared to the typical daily volume of 256 put options.

More Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: GLOW2 Phase 3 topline: Zenkuda met the primary endpoint with a large advantage over sham (62.5% of Zenkuda patients achieved ≥2‑step DRSS improvement vs 3.3% for sham), supporting efficacy on a 6‑month dosing interval. Article Title
• Positive Sentiment: Regulatory/readout impact: Analysts and industry press say the results, together with prior GLOW1 data, clear the path toward a BLA submission and potential commercialization if safety and regulatory review are favorable. Article Title
• Positive Sentiment: Market reaction and coverage: Major outlets reported the success and the stock jumped on the news amid markedly elevated volume, reflecting investor re-pricing of Kodiak toward a late‑stage biotech with a near-term regulatory catalyst. Article Title
• Neutral Sentiment: Broad media pickup: Multiple outlets (Barron’s, MarketWatch, Yahoo, Seeking Alpha) amplified the news, increasing investor attention and liquidity but not adding new clinical detail beyond the topline announcement. Article Title
• Negative Sentiment: Volatility and hedging signs: There was an unusual spike in put option buying (≈3,472 puts, a ~1,256% increase vs typical daily put volume), suggesting some investors are hedging or speculating on a pullback; the stock now trades at much higher valuations and carries a high beta, increasing short‑term downside risk.

Analyst Upgrades and Downgrades

KOD has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. UBS Group initiated coverage on Kodiak Sciences in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $38.00 price objective on shares of Kodiak Sciences in a report on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Kodiak Sciences presently has an average rating of “Moderate Buy” and an average price target of $28.29.

Kodiak Sciences Stock Up 74.8%

KOD opened at $39.76 on Friday. The firm’s fifty day simple moving average is $24.95 and its two-hundred day simple moving average is $21.62. Kodiak Sciences has a 52-week low of $1.92 and a 52-week high of $40.46. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -9.65 and a beta of 2.61.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Boone Capital Management LLC acquired a new position in shares of Kodiak Sciences during the third quarter valued at approximately $11,719,000. TD Asset Management Inc acquired a new stake in shares of Kodiak Sciences in the third quarter worth approximately $992,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Kodiak Sciences during the third quarter worth approximately $488,000. Panagora Asset Management Inc. increased its position in shares of Kodiak Sciences by 28.5% during the second quarter. Panagora Asset Management Inc. now owns 131,122 shares of the company’s stock worth $489,000 after purchasing an additional 29,113 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in Kodiak Sciences in the 3rd quarter valued at $204,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.